Search

Your search keyword '"Gonzàlez Santiago, S."' showing total 16 results
Start Over Author "Gonzàlez Santiago, S."
16 results on '"Gonzàlez Santiago, S."'

1. 197P ATREZZO trial (SOLTI-1907): A phase II trial targeting estrogen receptor negative or PAM50 non-luminal disease with atezolizumab in combination with trastuzumab and vinorelbine in HER2-positive (HER2+) advanced breast cancer (ABC) - Interim analysis

Author

Ciruelos, E.M., Ortega, P. Tolosa, Bofill, F.J. Salvador, González-Santiago, S., Miro, C.R. Albacar, Escrivá-De-Romaní, S., Gonzalez, A. Lopez, Simon, S. Pernas, Ponce, J., Martínez-Sáez, O., Cejalvo, J.M., Martorell, A. Perello, López-Barajas, I. Blancas, Guerra, J.A., Torres, E. Sanfeliu, Sanchez, C.A. Rodríguez, Villanueva, L., Villacampa, G., Prat, A., and Pascual, T.

Published
2023
Full Text
View/download PDF

2. 116P Time and motion randomised study of a subcutaneous (SC) pertuzumab and trastuzumab fixed-dose combination (PH FDC) for the treatment of HER2-positive early breast cancer (HER2 EBC): PHaTiMa

Author

González-Santiago, S., López-Miranda, E., Escrivá-De-Romaní, S., Jiménez-Rodríguez, B., Antolín-Novoa, S., González-Cortijo, L., Fernández-Morales, L.A., Galve-Calvo, E., Martorell, A. Perello, Arroyo-Rivera, I., García-Bernáldez, C., Lagunar-Ruiz, J., and Gavilá-Gregori, J.

Published
2023
Full Text
View/download PDF

3. Treatment and long-term clinical outcomes of incidental pulmonary embolism in patients with cancer: An international prospective cohort study

Author

Kraaijpoel, Noémie, Bleker, Suzanne M., Meyer, Guy, Mahé, Isabelle, Muñoz, Andrés, Bertoletti, Laurent, Bartels-Rutten, Annemarieke, Beyer-Westendorf, Jan, Porreca, Ettore, Boulon, Carine, van Es, Nick, Iosub, Diana I., Couturaud, Francis, Biosca, Mercedes, Lerede, Teresa, Lacroix, Philippe, Maraveyas, Anthony, Aggarwal, Anita, Girard, Philippe, Büller, Harry R., di Nisio, Marcello, Accassat, S., Aquilant, S., Assaf, J. D., Baars, J., Beenen, L. M., Bergmann, J. F., Bozas, G., Caliandro, R., Carrier, M., Confrere, E., Constans, J., Désormais, I., Dublanchet, N., Endig, S., Falanga, A., Falvo, N., Ferrer Pérez, Al, García Escobar, I., Gonzàlez Santiago, S., Grange, C., Helfer, H., Kleinjan, A., Lalezari, F., de Magalhaes, E., Marten, S., Martinez del Prado, P., Otten, H. M., Paleiron, N., Pérez Ramírez, S., ACS - Pulmonary hypertension & thrombosis, Vascular Medicine, and ARD - Amsterdam Reproduction and Development

Subjects
Cancer Research, medicine.medical_specialty, business.industry, Incidence (epidemiology), Cancer, 030204 cardiovascular system & hematology, medicine.disease, Pulmonary embolism, 03 medical and health sciences, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Internal medicine, medicine, Cumulative incidence, Clinical significance, Lung cancer, Prospective cohort study, business, Cohort study
Abstract

PURPOSE Pulmonary embolism is incidentally diagnosed in up to 5% of patients with cancer on routine imaging scans. The clinical relevance and optimal therapy for incidental pulmonary embolism, particularly distal clots, is unclear. The aim of the current study was to assess current treatment strategies and the long-term clinical outcomes of incidentally detected pulmonary embolism in patients with cancer. PATIENTS AND METHODS We conducted an international, prospective, observational cohort study between October 22, 2012, and December 31, 2017. Unselected adults with active cancer and a recent diagnosis of incidental pulmonary embolism were eligible. Outcomes were recurrent venous thromboembolism, major bleeding, and all-cause mortality during 12 months of follow-up. Outcome events were centrally adjudicated. RESULTS A total of 695 patients were included. Mean age was 66 years and 58% of patients were male. Most frequent cancer types were colorectal (21%) and lung cancer (15%). Anticoagulant therapy was initiated in 675 patients (97%), of whom 600 (89%) were treated with low-molecular-weight heparin. Recurrent venous thromboembolism occurred in 41 patients (12-month cumulative incidence, 6.0%; 95% CI, 4.4% to 8.1%), major bleeding in 39 patients (12-month cumulative incidence, 5.7%; 95% CI, 4.1% to 7.7%), and 283 patients died (12-month cumulative incidence, 43%; 95% CI, 39% to 46%). The 12-month incidence of recurrent venous thromboembolism was 6.4% in those with subsegmental pulmonary embolism compared with 6.0% in those with more proximal pulmonary embolism (subdistribution hazard ratio, 1.1; 95% CI, 0.37 to 2.9; P = .93). CONCLUSION In patients with cancer with incidental pulmonary embolism, risk of recurrent venous thromboembolism is significant despite anticoagulant treatment. Patients with subsegmental pulmonary embolism seemed to have a risk of recurrent venous thromboembolism comparable to that of patients with more proximal clots.

Published
2019
Full Text
View/download PDF

4. 795P Tolerability and effectiveness of niraparib in long-term responders with platinum-sensitive recurrent ovarian cancer (GEICO-88R study)

Author

Cueva Banuelos, J.F., Salvador Coloma, C., Galvez Montosa, F., Ferreiro Quintana, J., Cros Costa, S., González-Santiago, S., Cassinello, J.G., Romeo Marin, M., Reche, P., Soriano Tabares, M.L., Valero Arbizu, M., Rubio Perez, M.J., Oré Arce, H.M., Gaba Garcia, L., Gordon Santiago, M.D.M., Gomez Raposo, C., Hernando Polo, S., Marquez Vazquez, R., Fuentes Pradera, J., and Gonzalez Martin, A.

Published
2023
Full Text
View/download PDF

5. P006 Randomized Phase II trial evaluating three anti-diarrhoeal prophylaxis strategies in patients with HER2+/HR+ early breast cancer treated with extended adjuvant neratinib (DIANER GEICAM/2018-06)

Author

González-Santiago, S., Gil-Gil, M., Carrasco, E., Martínez-Jáñez, N., Adamo, B., Antolín, S., Alonso, J.L., Vethencourt, A., Martínez-Vila, C., Galve, E., Rojo, F., Caballero, R., Casas, M., Cortazar, E., McCulloch, L., Vedovato, J.-C., and Martín, M.

Published
2023
Full Text
View/download PDF

6. 12P Prevalence of functional and genomic homologous recombination deficiency (HRD) in germline RAD51C/D patients

Author

Llop-Guevara, A., Torres-Esquius, S., Romey, M., Gutierrez-Enriquez, S., Nuciforo, P.G., Diez, O., Llort Pursals, G., Teule, A., Vallmajó, A., Diaz De Corcuera, I., Chirivella Gonzalez, I., Gonzalez Santiago, S., Sanchez Henarejos, P., Sanz Buxo, J., Guillen Ponce, C., Sanchez, A.B., Brunet Vidal, J.M., Denkert, C., Serra Elizalde, V., and Balmaña, J.

Published
2022
Full Text
View/download PDF

7. 330TiP Trastuzumab deruxtecan (T-DXd; DS-8201) in HER2-positive (HER2+) and HER2-low expressing (HER-LE) metastatic breast cancer (MBC) with brain metastases (BM) and/or leptomeningeal carcinomatosis (LMC): DEBBRAH

Author

Vaz Batista, M., Pérez-Garcia, J.M., Llombart Cussac, A., Cortez, P., Ruiz Borrego, M., De La Haba, J., Cejalvo, J.M., Racca, F., Servitja, S., Blanch, S., Lema, L., Galàn Garmaje, M., Fernández-Abad, M., Fernández, A., Iranzo, V., González-Santiago, S., Gion, M., Nave, M., Cortés, J., and Braga, S.

Published
2021
Full Text
View/download PDF

8. 332TiP SOLTI-1907 ATREZZO: Targeting hormonal receptor negative (HR-) or PAM50 non-luminal disease with atezolizumab in combination with trastuzumab and vinorelbine in HER2+ metastatic breast cancer (MBC)

Author

Ciruelos, E.M., Pernas, S., Perelló, A., Lopez, A., Salvador Bofill, F.J., Cejalvo, J.M., Blancas, I., Ponce Lorenzo, J., Servitja, S., Perez, M., Cruz, J., Albacar, C., Escrivá-de-Romaní, S.I., Guerra, J.A., González-Santiago, S., Sanfeliu, E., Rodriguez, C., Tolosa, P., Ferrero-Cafiero, J.M., and Prat, A.

Published
2021
Full Text
View/download PDF

9. Treatment and long-term clinical outcomes of incidental pulmonary embolism in cancer patients: an international prospective cohort study

Author

Kraaijpoel, N., primary, Bleker, S.M., additional, van Es, N., additional, Mahé, I., additional, Muñoz, A., additional, Meyer, G., additional, Planquette, B., additional, Sanchez, O., additional, Bertoletti, L., additional, Accassat, S., additional, de Magalhaes, E., additional, Baars, J., additional, Rutten, A., additional, Lalezari, F., additional, Beyer-Westendorf, J., additional, Endig, S., additional, Marten, S., additional, Porreca, E., additional, Rutjes, A.W., additional, Russi, I., additional, Constans, J., additional, Boulon, C., additional, Kleinjan, A., additional, Beenen, L.F.M., additional, Iosub, D., additional, Piovella, F., additional, Couturaud, F., additional, Tromeur, C., additional, Biosca, M., additional, Assaf, J.D., additional, Helfer, H., additional, Pinson, M., additional, Lerede, T., additional, Falanga, A., additional, Lacroix, P., additional, Désormais, I., additional, Maraveyas, A., additional, Bozas, G., additional, Aggarwal, A., additional, Rickles, F., additional, Girard, P., additional, Caliandro, R., additional, Martinez del Prado, P., additional, de Prado Maneiro, C., additional, García Escobar, I., additional, Gonzàlez Santiago, S., additional, Schmidt, J., additional, Dublanchet, N., additional, Aquilanti, S., additional, Confrere, E., additional, Paleiron, N., additional, Grange, C., additional, Sevestre, M.A., additional, Ferrer Pérez, A.I., additional, Salgado Fernández, M., additional, Falvo, N., additional, Thaler, J., additional, Otten, H.M., additional, Carrier, M., additional, Bergmann, J.F., additional, Büller, H.R., additional, and Di Nisio, M., additional

Published
2018
Full Text
View/download PDF

10. 336P - Interim results from CompLEEment-1 (A phase IIIb study of ribociclib and letrozole as first-line therapy for advanced breast cancer in an expanded population): Spanish cohort results

Author

Salvador, J., Ciruelos, E.M., Jiménez-Rodríguez, B., De La Cruz, L., Villanueva Vázquez, R., De Toro, R., Antón, A., Moreno, F., Álvarez, I., Quiroga, V., de la Haba, J., González-Santiago, S., Díaz, N., Barnadas, A., Cantos, B., Delgado Mingorance, I., Bellet Ezquerra, M., Martín, M., Martínez, N., and Vicente, E.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results